JP5884217B2 - 大豆のRhizopusmicrosporusvar.oligosporus発酵によるエストロゲン活性含有食品とその製法 - Google Patents
大豆のRhizopusmicrosporusvar.oligosporus発酵によるエストロゲン活性含有食品とその製法 Download PDFInfo
- Publication number
- JP5884217B2 JP5884217B2 JP2009233842A JP2009233842A JP5884217B2 JP 5884217 B2 JP5884217 B2 JP 5884217B2 JP 2009233842 A JP2009233842 A JP 2009233842A JP 2009233842 A JP2009233842 A JP 2009233842A JP 5884217 B2 JP5884217 B2 JP 5884217B2
- Authority
- JP
- Japan
- Prior art keywords
- estrogen
- activity
- food
- soybean
- vertebrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940011871 estrogen Drugs 0.000 title claims description 43
- 239000000262 estrogen Substances 0.000 title claims description 43
- 235000013305 food Nutrition 0.000 title claims description 30
- 230000000694 effects Effects 0.000 title claims description 22
- 238000004519 manufacturing process Methods 0.000 title claims description 16
- 235000010469 Glycine max Nutrition 0.000 title claims description 13
- 244000068988 Glycine max Species 0.000 title claims description 13
- 238000000855 fermentation Methods 0.000 title claims 2
- 230000004151 fermentation Effects 0.000 title claims 2
- 241000235527 Rhizopus Species 0.000 title description 2
- 238000000034 method Methods 0.000 claims description 11
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 10
- 239000013589 supplement Substances 0.000 claims description 6
- 230000001766 physiological effect Effects 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 241000593344 Rhizopus microsporus Species 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims 1
- 238000012790 confirmation Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 16
- 239000000126 substance Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000001076 estrogenic effect Effects 0.000 description 9
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000003054 hormonal effect Effects 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 235000020712 soy bean extract Nutrition 0.000 description 6
- 108020005544 Antisense RNA Proteins 0.000 description 5
- 238000000018 DNA microarray Methods 0.000 description 5
- 239000003184 complementary RNA Substances 0.000 description 5
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 5
- 235000008696 isoflavones Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 150000002515 isoflavone derivatives Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 235000021404 traditional food Nutrition 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000013548 tempeh Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004735 virus-associated carcinogenesis Effects 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Description
ヒト乳がん由来のMCF−7細胞を24ウェルプレートに播種し、5%炭酸ガス(CO2)の存在下、37℃で1日培養する。培地としては、フェノールレッド不含RPMI 1640培地に活性炭で処理した牛胎児血清を10%添加したものを用いる。24時間後、新しい培地に交換し、試験物質を添加した後に5%炭酸ガス(CO2)の存在下、37℃で3日間培養する。その後、培地を捨てて10%トリクロロ酢酸を加え、4℃で30分間静置。トリクロロ酢酸を純水で洗浄して、0.4%SRB(Sulforhodamine B)を含む1%酢酸で20分間染色する。余分なSRBを1%酢酸で洗浄後、波長490nmにおける吸光度(A490)を定量した。比較のために、10nMエストロゲン標準物質(E2)による試験を並行して行う。試験物質による増殖への影響は、エストロゲン標準物質によるA490の増大に対する比率(%)の平均値および標準偏差で評価した(図1)。
細胞増殖試験に用いたMCF−7細胞を、今度は同培地を満たした10cmシャーレに播種し、細胞増殖試験と同様の条件で3日間培養、トリプシンを加え37℃、5分間処理して細胞を回収した後に、新しい培地に播種し、試験物質を添加して3日間培養する。その後、ISOGEN(ニッポンジーン)0.5ml加えて細胞溶解液を回収し、0.15mlのクロロホルムを加えて1分間激しく攪拌した後に5分間静置、20,000xgで4℃、15分間の遠心分離後、水層を回収、等量の2−プロパノールを加えて混和する。室温で5分間静置、20,000xgで4℃、10分間の遠心分離を行い、沈殿を75%エタノールで洗ってから15分間風乾、DEPC処理水に溶解する。対照として、試験物質を添加しない未処理細胞からのTotal RNAも同様にして調製する。
Total RNAからのアンチセンスRNA(aRNA)の合成は、RiboAMP RNA Amplification Kit(タカラ)を用い、添付のプロトコールに従って行っている。aRNAから蛍光標識cDNAの調製は、Atlas Power Script Fluorescent labeling Kit(タカラ)を用い、添付のプロトコールに従う。試験物質で処理した細胞由来のaRNAからはCy3で蛍光標識してcDNAを調製し、未処理細胞由来のaRNAからはCy5で蛍光標識したcDNAを調製している。蛍光標識cDNAの精製はCyScribe GFX Purification Kit(GEヘルスケア)を用る。精製したCy3標識cDNAとCy5標識cDNAをハイブリダイゼーション緩衝液(5xSSC,0.5%SDS。1xSSCは150mM塩化ナトリウムと15mMクエン酸ナトリウムから成る)と混ぜ、DNAマイクロアレイ(EstrArray)に加えて、65℃で一晩静置。その後、同アレイを0.2%SDSを含む2xSSC、0.2%SDSを含む0.2xSSC、さらに0.2xSSCの順でそれぞれ5分間洗浄して乾燥する。これをChipReader(Virtek)でスキャンし、IPLab software(Scanalytics)で解析する。各遺伝子のCy3の蛍光強度とCy5の蛍光強度との比(Cy3/Cy5)を計算し、補正用コントロール遺伝子の比(Cy3/Cy5)の平均値で割って補正する。
高齢化社会では中高年、特に女性の血中エストロゲンの枯渇は、更年期障害、骨粗しょう症、リュウーマチなど医療費を押し上げる要因のひとつになっている。エストロゲン補充は現在はヒト胎盤抽出物などが用いられ、ウィルス感染や発がんの危険性を伴う高価で危険を伴う医療行為である。
本発明により、エストロゲン補充は極めて安全で、手軽なものとなる。このため、高齢者のQOL向上と医療費抑制に貢献できると考える。
Claims (3)
- 脊椎動物エストロゲンに代替可能なエストロゲン活性含有食品を得ることを目的とした食品の製造方法であり、大豆を原料とし、ヒト細胞を用いた生理活性測定により製造工程で同活性が現れ製品中にも同活性が存在することの確認作業を伴う、Rhizopus microsporus var.oligosporusによる発酵と同活性を抽出する工程を含む食品の製造法。
- 脊椎動物エストロゲンに代替可能なエストロゲン活性含有食品を得ることを目的とした食品の製造方法であり、請求項1の方法を用いる、大豆皮、大豆胚芽、または大豆子葉由来のエストロゲン活性含有食品の製造法。
- 脊椎動物エストロゲンに代替可能なエストロゲン活性含有食品を含む製品の製造方法であり、請求項2のエストロゲン活性含有食品を、飲料、食品、サプリメント、化粧品、医薬品などに添加することによって得られるエストロゲン活性含有製品の製造法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009233842A JP5884217B2 (ja) | 2009-09-14 | 2009-09-14 | 大豆のRhizopusmicrosporusvar.oligosporus発酵によるエストロゲン活性含有食品とその製法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009233842A JP5884217B2 (ja) | 2009-09-14 | 2009-09-14 | 大豆のRhizopusmicrosporusvar.oligosporus発酵によるエストロゲン活性含有食品とその製法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011055819A JP2011055819A (ja) | 2011-03-24 |
JP5884217B2 true JP5884217B2 (ja) | 2016-03-15 |
Family
ID=43944211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009233842A Expired - Fee Related JP5884217B2 (ja) | 2009-09-14 | 2009-09-14 | 大豆のRhizopusmicrosporusvar.oligosporus発酵によるエストロゲン活性含有食品とその製法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5884217B2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6051436B2 (ja) * | 2011-12-07 | 2016-12-27 | 国立研究開発法人産業技術総合研究所 | レッドクローバーと亜麻種子由来のエストロゲン類似活性組成物 |
JP2019062741A (ja) * | 2016-02-17 | 2019-04-25 | 池田食研株式会社 | 膵リパーゼ阻害用組成物及び膵リパーゼ阻害用組成物の製造方法 |
WO2023120006A1 (ja) * | 2021-12-23 | 2023-06-29 | 株式会社ユーグレナ | テンペ菌発酵産物、テンペ菌発酵産物原料及びテンペ菌発酵産物の製造方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH567377A5 (ja) * | 1973-05-28 | 1975-10-15 | Nestle Sa | |
JP2000157207A (ja) * | 1998-11-26 | 2000-06-13 | Noriyuki Oikawa | 機能性食品 |
JP2005034145A (ja) * | 2003-06-27 | 2005-02-10 | Mitsukan Group Honsha:Kk | イソフラボンアグリコンを高濃度で含有する大豆類の製造方法 |
JP2006223141A (ja) * | 2005-02-16 | 2006-08-31 | Kimiko Mano | 健康食品 |
JP2007110946A (ja) * | 2005-10-19 | 2007-05-10 | Kume Quality Prod Kk | 糸状菌およびその用途 |
JP2007215406A (ja) * | 2006-02-14 | 2007-08-30 | Fuji Oil Co Ltd | 大豆胚軸を利用した健康食品 |
-
2009
- 2009-09-14 JP JP2009233842A patent/JP5884217B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2011055819A (ja) | 2011-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Danciu et al. | Main isoflavones found in dietary sources as natural anti-inflammatory agents | |
CN100560579C (zh) | 红豆越橘提取物及其制备方法和应用 | |
Zhao et al. | Eucommia ulmoides leaf extract alters gut microbiota composition, enhances short‐chain fatty acids production, and ameliorates osteoporosis in the senescence‐accelerated mouse P6 (SAMP6) model | |
TWI454269B (zh) | 由文冠果(xanthoceras sorbifolia)單離之化合物、其製備方法以及其用途 | |
CN105255698B (zh) | 一种富含功能活性因子的萌动荞麦醋及其制备方法 | |
JP5884217B2 (ja) | 大豆のRhizopusmicrosporusvar.oligosporus発酵によるエストロゲン活性含有食品とその製法 | |
KR20120126746A (ko) | 고품질 돈육 생산을 위한 발아 및 발효콩을 이용한 기능성 양돈사료 첨가제 및 그 제조방법 | |
Otieno et al. | Optimizing process of brewing onion peel tea using a response surface methodology | |
CN1559290A (zh) | 一种保健食品软胶囊及制备方法 | |
CN116869853A (zh) | 鲟鱼籽肽粉及其制备方法、化妆品组合物 | |
Trinidad-Calderón et al. | Acetone-precipitated zein protein hydrolysates from blue-maize selectively target hepatocellular carcinoma and fibroblasts in a dose-dependent manner | |
CN110585273A (zh) | 具有脂肪酸合酶抑制活性的牡丹籽粕提取物及其制备方法与应用 | |
CN106543197B (zh) | 一种补骨脂素席夫碱类衍生物及用途 | |
AU2012354703B2 (en) | Hydroxymethylfurfural derivative | |
JP2017055665A (ja) | 有用産物の生産方法 | |
Hu et al. | Characterization of precipitation from citrus vinegar during ageing: chemical constituents, formation mechanism and anti-proliferative effect | |
CN105362326B (zh) | 一种从不结球白菜提取天然活性物质的方法及其应用 | |
JP5802880B2 (ja) | 脊椎動物エストロゲンに代替可能な植物抽出物の細胞生物学的同定法 | |
JP2019532039A (ja) | 花粉及び/又は雌しべの抽出物を含む組成物、調製方法、並びに関連する使用 | |
JP5526948B2 (ja) | 2,6−ジプレニル−4−ビニルフェノールの生成方法 | |
CN107298686B (zh) | 一种补骨脂素胺类衍生物及用途 | |
KR100945670B1 (ko) | 청국장 분말을 포함하는 건강 식품 조성물 | |
CN110215472A (zh) | 一种组合物及其在防治手机辐射药物/保健品中的应用 | |
Park et al. | Fermented garlic extract increases oxygen consumption and UCP-1 mRNA expression in human adipose-derived stem cells | |
KR101734022B1 (ko) | 미생물 및 천연효소를 이용한 발효황금 천마 복합 추출 분말의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120618 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120918 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130219 |
|
A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20130910 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140217 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140414 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150404 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20150630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150929 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160120 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5884217 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |